Skip to content

Estimation of the optimum dose of intrathecal administration of ropivacaine combined with dexmedetomidine for cesarean section

Estimation of the optimum dose of intrathecal administration of ropivacaine combined with dexmedetomidine for cesarean section

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055928
Enrollment
Unknown
Registered
2022-01-26
Start date
2022-01-26
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cesarean section under spinal anesthesia

Interventions

group 1 :ropivacaine 10mg +dexmedetomidine
group 2 :ropivacaine 8mg +dexmedetomidine

Sponsors

Guangzhou Women and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Elective cesarean section in healthy parturient

Exclusion criteria

Exclusion criteria: Patients with respiratory, cardiovascular, renal, hepatic, endocrine and neurological diseases were excluded.

Design outcomes

Primary

MeasureTime frame
The success or failure of the intrathecal block;

Secondary

MeasureTime frame
Sensory block leve;Motor block level;Visceral traction response;Muscle relaxation;Shivering score;Sedation score;Operative and postoperative side effects;Operative and postoperative pain scores;Time to first required supplemental analgesia after surgery;Satisfaction;Time to first urination after the extubation of the catheters;Time of first getting out of bed activity;

Countries

China

Contacts

Public ContactMo Xiaofei

Guangzhou Women and Children's Medical Center

13560336485@163.com+86 13560336485

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026